natgillin/translations-raw huggingface dataset:
The recombinant Gram-negative bacterial strain of any one of claims 2-3, wherein the recombinant Gram-negative bacterial strain is a Yersinia strain and wherein said Yersinia strain is wild type or deficient in the production of at least one T3SS effector protein and wherein the delivery signal from the bacterial T3SS effector protein comprises the N-terminal 138 amino acids of the Y. enterocolitica YopE effector protein or, wherein the recombinant Gram-negative bacterial strain is a Salmonella strain and wherein said Salmonella strain is wild type or deficient in the production of at least one T3SS effector protein and wherein the delivery signal from the bacterial T3SS effector protein comprises the S. enterica SteA effector protein or the N-terminal 81 or 105 amino acids of the S. enterica SopE effector protein. 
Rekombinantni Gram-negativan bakterijski soj iz bilo kojeg od zahtjeva 2 – 3, naznačen time da je rekombinantni Gram-negativan bakterijski soj Yersinia soj i pri čemu je naveden Yersinia soj divlji soj ili deficitaran u proizvodnji barem jednog T3SS proteina efektora i pri čemu signal isporuke od bakterijskog T3SS proteina efektora obuhvaća N-terminalne 138 aminokiseline Y. enterocolitica YopE proteina efektora ili, pri čemu je rekombinantni Gram-negativan bakterijski soj Salmonella soj i pri čemu je naveden Salmonella soj divlji soj ili deficitaran u proizvodnji barem jednog T3SS proteina efektora i pri čemu signal isporuke od bakterijskog T3SS proteina efektora obuhvaća S. enterica SteA protein efektor ili N-terminalne 81 ili 105 aminokiseline S. enterica SopE protein efektora.
A compound according to claim 11, wherein the compound has the following formula: 
Spoj iz bilo kojeg prethodnog patentnog zahtjeva, gdje spoj ima sljedeću formulu:
a binder selected from polyvinylpyrrolidone, polyethylene glycols, co-polymers of vinyl acetate and vinylpyrrolidone, potato starch and corn starch, and a combination thereof; a humectant selected from glycerol, propylene glycol, cetyl alcohol, glycerin monostearate and polyethylene glycols, and a combination thereof; and a natural or artificial beef or meat flavor. 
Cc) vezivo odabrano od polivinilpirolidona, polietilenglikola, kopolimera vinilacetata i vinilpirolidona, krumpirov škrob i kukuruzni škrob, ili njihove kombinacije; d) ovlaživač odabran od glicerola, propilenglikola, cetilnog alkohola, glicerin-monostearata i polietilenglikola, ili njihove kombinacije; i e) aroma prirodne ili umjetne govedine ili aroma mesa.
Comparative Example 5 Aerosol Administration of 30 mg/ml and 50 mg/ml Solutions of Levofloxacin Formulated with MgCl2 
Aerosol za uporabu sukladno patentnom zahtjevu 1 sadrži od 80 mg/ml do 120 mg/ml levofloksacina.
A pharmaceutical composition as defined in any one of claims 1 to 23 for use in a method for treating a pulmonary disease or disorder in a patient. 
Ko-suspenzija u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačena time što je namijenjena upotrebi u liječenje pacijenta koji boluje od upalne ili opstruktivne plućne bolesti ili stanja.
said first and second DNA molecule comprise at least 30 contiguous nucleotides of SEQ ID NO: 3, SEQ ID NOL: 4 or SEQ ID NO: 5. 
se spomenute obje DNA molekule sastoje od najmanje 30 u nizu poredanih nukleotida SEQ ID NO: 3, SEQ ID NO: 4 ili SEQ ID NO: 5.
In the embodiment of Fig. 5 grooves 22 are provided in the circumference of capsule holder 13, which grooves 22 act to evacuate water which could settle or accumulate on the upper surface of the capsule holder 13 or dripping out of the capsule before the capsule has been removed. 
U ostvarenju iz slike 5 predviđeni su utori 22 na obodu držača 13 čahure, koji utori djeluju tako da odvode vodu koja bi se mogla skupiti ili akumulirati na gornjoj površini držača čahure 13 ili koja bi mogla kapati iz čahure prije nego što se čahura ukloni.
Coding and decoding images with sign data hiding A method is provided for coding at least one image split up into partitions, a current partition to be coded containing data, at least one data item of which is allotted a sign. 
Postupak kodiranja barem jedne slike podijeljene u particije, jedne trenutne particije (Bi) za kodiranje koja sadrži podatke pri čemu je barem jednom podatku dodijeljen predznak, a podaci su koeficijenti direktne transformacije, te je postupak kodiranja naznačen time da se za trenutnu particiju provode slijedeći koraci:
wherein said derivative has three positive charges at physiological pH, and pharmaceutically acceptable prodrugs and salts thereof. 
gdje taj derivat ima tri pozitivna naboja pri fiziološkom pH, i njegovi farmaceutski prikladni prolijekovi i soli.
In some embodiments, the process is characterized by at least one of the following features (1)-(5). 
Postupak prema patentnom zahtjevu 49, naznačen najmanje jednom od slijdećih karakteristika (1)-(5):
Oxycodone HCl, lactose, and povidone are placed into a fluid bed granulator/dryer (FBD) bowl, and the suspension sprayed onto the powder in the fluid bed. 
2. < Oksikodon HCI, laktoza, i povidon su postavljeni u fluidiziranom sloju u posudu granulatora/sušilice (FBD), te je suspenzija raspršena u prah u fluidiziranom sloju.
According to a particular aspect of the present invention, a receiving antenna 42 and a transmitting antenna 44, both formed on the same annular support and connected to electronic circuit 4, are co-molded directly inside lateral walls 9, 10, 11, 12 . 
U skladu s osobitim aspektom predmetnog izuma, prijemna antena 42 i predajna antena 44, obje oblikovane na istom prstenastom osloncu i povezane na elektronski krug 4, su zajedno zalivene izravno unutar bočnih stijenki 9, 10, 11, 12.
The fuel pump nozzle as claimed in claim 5, wherein the lever (10) includes a latching surface (22) for co-operating with the at least one hold-open catch (14). 
Pištolj za istakanje goriva bilo prema zahijevu 5 ili zahtjevu 6, naznačen time da polugica (10) sadrži površinu za blokiranje (22), koja predstavlja podlogu za djelovanje jezičca za držanje u otvorenom položaju (15).
a top pumping line vessel-side part section (32) connected in a rotatable and movable manner with an extremity (19) to the vessel (2) by means of the trunnion slide connection (20); 
gornji dio strane plovila za liniju za pumpanje (32) spojen na rotatabilan i pomičan način s ekstremitetom (19) s plovilom (2) pomoću klizne veze rame (20);
The liquefied gas treatment system according to claim 5, wherein the boil-off gas supplied to the heat exchanger (21) is a boil-off gas compressed while passing through all of the plurality of compression means included in the compressor (13,13a,13b). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se tekuću komponentu BOG-a, koji se dekomprimira u plinovito-tekuće miješano stanje prilikom prolaska kroz element za dekomprimiranje (22), vraća u spremnik za teret (1;11)
A method according to any preceding clause wherein the size of the particles of the surface material is such that at least 50%, preferably at least 70% by weight of the particles have a size of at least 0.5 mm, preferably at least 1.0 mm. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, da je veličina čestica površinskog materijala (30) takva, da najmanje 50%, poželjno najmanje 70% od mase čestica, ima veličinu od najmanje 0,5 mm, poželjno najmanje 1,0 mm.
The pharmaceutical composition according to claim 16, which is to be administered intradermally, in particular by tattooing. 
Farmaceutski sastav prema patentnom zahtjevu 3, gdje se farmaceutski sastav primjenjuje intraperitonealno, intramuskularno, intravenozno, intranazalno, potkožno, intradermalno ili intratekalno.
A composition according to claim 1 or 2, wherein R1 is H. 
Pripravak u skladu sa zahtjevom 1 ili 2, naznačen time, da R1 je H.
a compound of formula HO-R4-R5-OH, wherein R4 and R5 are as defined above; and an organic solvent that forms an azeotrope with water; heating the solution of step (a) at reflux, with azeotropic removal of water, to form a boronic ester of formula (III): wherein R1, R4, and R5 are as defined above; 
(ii) spoj formule HO-R"-R*-OH, gdje su R" i R? kao što su definirani u prethodnom tekstu; i (ili) organsko otapalo koje formira azeotrop sa vodom; zagrijavanje otopine iz koraka (a) na refluksu, sa azeotropnim uklanjanjem vode, da bi se formirao ester organoborne kiseline formule (717):
A method according to paragraph 1 or 2, characterised in that at least one wall of the casting mould is moved during the period of time which is about 25% before the end of the steaming phase and about 25% from the beginning of the steaming phase. 
Postupak prema zahtjevu 1 ili 2, naznačen time što se barem jedna stjenka kalupa za lijevanje pomiče tijekom vremenskog perioda koji je 25 % prije kraja parne faze i 25 % od početka faze hlađenja nakon parne faze.
is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl; 
je vodik, halogen, supstituirani ili nesupstituirani alkil, supstituirani ili nesupstituirani heteroalkil, supstituirani ili nesupstituirani cikloalkil, supstituirani ili nesupstituirani cikloalkenil, supstituirani ili nesupstituirani heterocikloalkil, supstituirani ili nesupstituirani heterocikloalkenil, supstituirani ili nesupstituirani aril, supstituirani ili nesupstituirani kondenzirani arilni prsten, ili supstituirani ili nesupstituirani heteroaril;
The hydrogel of any one of claims 1-2 and/or the lotion of any one of claims 3-6 for use in the prophylaxis and/or treatment for radiation dermatitis. 
Hidrogel iz bilo kojeg od zahtjeva 1 - 2 i/ili losion iz bilo kojeg od zahtjeva 3 - 6 za korištenje kod profilakse i/ili tretmana radijacijskog dermatitisa.
sealing the container and 
(li) zatvaranje spremnika i
at least one pulley for each of said systems for absorbing the force peaks of said ropes (4); 
- < najmanje jedan koloturnik za svaki od spomenutih sustava za apsorbiranje vršnih vrijednosti sile spomenute užadi (4)
The process of claim 1, wherein the substantially water insoluble polymer particles comprise from 5 wt % to 25 wt % of the total weight of the core particles, the substantially water insoluble particles and water soluble and/or water swellable material particles in the mixing step. 
Postupak sukladno zahtjevu 1, naznačeno time, da su se potpuno u vodi netopive polimerne čestice sastoje od 0 wt.% do 50 wt.%, ili od 5 wt. % do 25 wt. % ukupne težine čestica jezgre, potpuno u vodi netopivih čestica i u vodi topivih čestica koje su takođe bubre u vodi, kada se pomiješaju.
The method according to claim 1, wherein the hydrocarbon is ethane or ethene and wherein the second catalyst catalyzes de-carbonylation reactions. 
Metoda u skladu s patentnim zahtjevom 1, pri čemu je ugljikovodik etan ili eten i pri čemu drugi katalizator katalizira reakcije dekarbonilacije.
Parallel synthesis may be employed in the preparation of compounds, for example, where the intermediates possess an activated reaction center: such as but not limited to, the nitrogen of the triazolone, the nitrogen of the pyridazinone, a reactive heteroaryl chloride for Suzuki coupling chemistry or a carboxylic acid for amide coupling chemistry. 
Paralelna sinteza može su upotrijebiti u pripremi spojeva, npr., gdje međuspojevi imaju aktivirani reakcijski centar, kao Å to je, ali bez ograničenja, dušik triazolona, dušik piridazinona, reaktivni heteroaril klorid za Suzuki kemijske reakcije spajanja ili karboksilna kiselina za kemijske reakcije spajanja amida.
An isolated antibody or antigen-binding fragment thereof that specifically binds human angiopoietin-2 (hAng-2), wherein the antibody or antigen-binding fragment thereof comprises a heavy chain CDR-1 (HCDR1) having the amino acid sequence of SEQ ID NO:4, an HCDR-2 having the amino acid sequence of SEQ ID NO:6, an HCDR-3 having the amino acid sequence of SEQ ID NO:8, a light chain CDR-1 (LCDR-1) having the amino acid sequence of SEQ ID NO:12, an LCDR-2 having the amino acid sequence of SEQ ID NO:14, and an LCDR-3 having the amino acid sequence of SEQ ID NO:16. 
Izolirani ljudsko antitijelo ili fragment koji vezuje njegov antigen koji se konkretno vezuje za ljudski angiopoietin-2 (hAng2) uz Kp manji od 80 pM, ali ne ispoljava nikakvo vezivanje za hAng-1 kada se ispituje u testu rezonancije površinskih plazmona i koji se sastoji od CDR-I teškog lanca (HCDRI) sa sekvencijom aminokiseline SEQ ID NO:4, HCDR-2 sa sekvencijom aminokiseline SEQ ID NO:6 1 HCDR-3 sa sekvencijom aminokiseline SEQ ID NO:8, CDR-1 lakog lanca (LCDR-1) sa sekvencijom aminokiseline SEQ ID NO:12, LCDR-2 sa sekvencijom aminokiseline SEQ ID NO:14 i LCDR-3 sa sekvencijom aminokiseline SEQ ID NO:16.
The pyridine derivative or the pharmaceutically acceptable salt thereof, or the solvate thereof according to clause 14, wherein Z is Z1, and R6 and R7 are, on a phenyl ring, chlorine substituents at 2- and 5-positions, chlorine substituents at 3- and 5-positions, methyl substituents at 2- and 5-positions, trifluoromethyl substituents at 2- and 5-postions, or chlorine and methyl substituents at 2- and 5-positions, respectively; 
Derivat piridina ili njegova farmaceutski prihvatljiva sol, ili njegov solvat prema zahtjevu 12, naznačen time da Z je Z1, 1 R 1 Ri su, na fenilnom prstenu, klorovi supstituenti na 2- i 5-položaju, klorovi supstituenti na 3- i 5- položaju, metilni supstituenti na 2- i 5-položaju, trifluorometil supstituenti na 2- i 5-položaju, ili odgovarajući klorovi i metilni supstituenti na 2- i 5-položaju;
Use of a compound as claimed in claims 1-4 as an intermediate in the synthesis of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide (I) or a pharmaceutically acceptable salt thereof. 
Upotreba spoja kako je prijavljen u patentnim zahtjevima 1 - 3 kao međuprodukt u sintezi 6-(7-((1- aminociklopropil)metoksi)-6-metoksikinolin-4-iloksi)-N-metil-1-naftamida (D) ili odgovarajuće farmaceutski prihvatljive soli.
The method of claim 1, characterized in a 1-bit syntax element is used to indicate whether the current Intra mode for the current block is equal to a first MPM of said three MPMs. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se 1-bitni sintaksni element upotrebljava za ukazivanje je li trenutačni Intra mod za trenutačni blok jednak prvom MPM od navedena tri MPM.
Pharmaceutical compositions comprising the compounds of claims 1-2 in admixture with suitable carrier/excipients. 
Farmaceutski pripravci, naznačeni time što sadrže spojeve u skladu s patentnim zahtjevima 1-2, u smjesi s pogodnom podlogom odnosno pomoćnim tvarima.
According to a further feature of this aspect there is disclosed a method for treating a cancer (for example a cancer selected from leukaemia, multiple myeloma, lymphoma, bile duct, bone, bladder, brain/CNS, breast, colorectal, endometrial, gastric, head and neck, hepatic, lung, neuronal, oesophageal, ovarian, pancreatic, prostate, renal, skin, testicular, thyroid, uterine and vulval cancer) in a warm-blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore. 
Prema dodatnoj značajci ovog aspketa, objavljen je postupak za liječenje raka (na primjer, leukemije, multiplog mijeloma, limfoma, žuči, kosti, mjehura, mozga/CNS-a, grudi, kolorektalnog, endometrialnog, gastričkog, glave i vrata, hepatičkog, plućnog, neuronalnog, ezofagalnog, jajnika, pankreasa, prostate, bubrežnog, kože, testikularnog, tiroidnog, uterinug i vulvarnog raka) u toplokrvnoj životinji, poput čovjeka, kojoj je takvo liječenje potrebno, a koji se sastoji od davanja spomenutoj životinji efektivne doze derivata kinazolina prikazanog Formulom I ili njegove farmaceutski prihvatljive soli, u skladu sa definicijom u gornjem tekstu.
wherein the unenriched renewable fuel oil is formed from mechanically grinding a cellulosic biomass followed by rapid thermal processing, exclusive of hydrodeoxygenation, hydrotreating, or catalytic processing, wherein the unenriched renewable fuel oil has a carbon content of at least 40 wt.% on a moisture-free basis, an oxygen content in the range of between 20-50 wt.% on a moisture-free basis, and a water content in the range of between 10-40 wt.%. 
80-99,95 wt. % sirovine frakcije petroleja; i ii)0,05-7 wt. % sirovine neobogaćenog obnovljivog ulja goriva, neobogaćeno obnovljivo ulje goriva nastaje mehaničkim mljevenjem celulozne biomase nakon čega slijedi brzo termalno procesiranje, isključivo od hidrodeoksigenacije, hidrotretiranja ili katalitičkog procesiranja, naznačen time što neobogaćeno obnovljivo ulje goriva ima u rasponu od između 35-80 wt. % sadržaja ugljika na bazi bez vlage;
Hydrolysis may be achieved in a mixture of organic solvent and water, particularly in a ratio of 10:1 to 1:10, preferably 8:1 to 1:3, more preferably 5:1 to 1:1, most preferably 4:1 to 2:1. The organic solvent can be selected from acetonitrile, acetone, methanol, ethanol, isopropanol and mixtures thereof, wherein acetonitrile is preferred. 
Postupak prema zahtjevu 9, naznačen time, da se reakcija provodi u mješavini organskog otapala i vode, posebno u omjeru od 10:1 do 1:10, poželjno od 8:1 do 1:3, još bolje od 5:1 do 1:1, najbolje od 4:1 do 2:1, pri čemu je organsko otapalo poželjno odabrano od acetonitrila, acetona, metanola, etanola, izopropanolainjihovih mješavina.
A baseplate (100, 100', 100'') as claimed in claim 29, wherein the loading means (9) comprise a ramp (9) provided adjacent to the rail seat region (110). 
Temeljna ploča (100, 100", 100") u skladu s patentnim zahtjevom 29, kod koje sredstvo za podizanje (9) ima rampu (9) koja se nalazi uz predio gdje naliježe tračnica (110).
a demodulator configured to demodulate the received signal by use of an Orthogonal Frequency Division Multiplexing(OFDM) method; 
demoduliranje primljenog emitiranog signala ortogonalnom modulacijskom metodom u frekvencijskoj domeni, OFDM;
After heating the reaction mixture at 90 °C for 18 hours, it was cooled to room temperature and HCl (3 mL, 3N) was added. 
Nakon zagrijavanja reakcijske smjese na 90" C tijekom 18 sati, ohladi se na sobnu temperaturu i doda se HCI (3 mL, 3N).
Also, up to about 5, preferably 1 to 2, weight percent of potassium carbonate may be included to improve lightability. 
Također se radi poboljšavanja mogućnosti paljenja mogu uključiti do oko 5, poželjno 1 do 2 masena postotka kalij-narbonata.
▪ R2 and R3 represent, independently of each other, a hydrogen atom or a (C1-C6)alkyl group; 
Spoj kriptoficina s formulom (I): pri čemu: ▪ R1 predstavlja skupinu (C1-C6)alkil;
an exit sequencer provided with means of vertical moving and configured to fulfill a sequencing function enabling a transfer, in a determined order, of said plurality of loads from said K levels of said exit transfer device to said at least one exit interface conveyor, wherein the control system is configured to control: at each iteration of a rising/descending cycle of the exit elevator, a transfer of a group of N loads from the at least one storage unit to the K levels of the exit elevator, with N being smaller than or equal to a capacity of the exit elevator in number of loads; 
– prilikom ponavljanja navedenog ciklusa dizanja i spuštanja, transport (61) skupine od N komada robe, iz najmanje jednog višerazinskog skladišnog kompleksa do K višetovarnih razina izlaznog dizala, gdje je N manji od ili jednak kapacitetu izlaznog dizala u broju robe, te uz, za svaku višetovarnu razinu izlaznog dizala, sekvenciranje robe, koju navodi sustav za navođenje, u skladu s ograničavanjem redoslijeda polaska N komada robe na navedenoj najmanje jednoj izlaznoj tekućoj vrpci;
It comprises a cabinet 2 for containing all the components of the apparatus 1, divided by a separating wall 24 in: 
Ovaj uređaj obuhvaća ormarić 2 koji sadržava sve komponente ovog uređaja, i koji je podijeljen pregradnim zidom 24 u:
The method according to claim 11 wherein the composition is a pharmaceutical aerosol formulation comprising a therapeutically effective amount of ciclesonide and a hydrofluorocarbon propellant and cosolvent in an amount effective to solubilize ciclesonide and optionally a surfactant. 
Uporaba prema zahtjevu 13, naznačena time, da sastav lijeka je farmaceutska aerosolna formulacija koja sadrži djelotvornu količinu ciklesonida i hidrofluorokarbonski stlačeni plin (propelant), poželjno odabran od 1,1,1,2- tetrafluoroetana, 1,1,1,2,3,3,3-heptafluoropropana i njihovih mješavina, te kootapalo u djelotvornoj količini za rastapanje ciklesonida i opcijski tenzida.
A pharmaceutically acceptable salt of a compound represented by the following formula: 
2. | Farmaceutski prihvatljiva sol spoja predstavljenog slijedećom formulom:
An Fc-containing molecule having decreased affinity for at least one FcY receptor as compared to a wildtype Fc, comprising an antibody Fc domain with a mutated IgG constant region, wherein amino acid residues 234, 235 and 237 defined by the EU numbering system comprise AAA, and wherein the Fc domain further comprises: 
Molekula koja sadrži Fc koji ima smanjen afinitet za najmanje jedan FcY receptor u usporedbi sa Fc divljeg tipa, sadržavajući Fc domenu antitijela sa mutiranom IgG2 konstantnom regijom, pri čemu su aminokiselinski ostaci 233, 234, 235, 237, i 238 definirani EU sistemom numeracije, obuhvaćajući sekvencu izabranu iz PAAAS (SEQ ID NO:5), i SAAAS (SEQ ID NO:6).
In some embodiments the methods provided herein are used to control undesirable vegetation in glyphosate-, glufosinate-, dicamba-, phenoxy auxins-, pyridyloxy auxins-, aryloxyphenoxypropionates-, acetyl CoA carboxylase (ACCase) inhibitors-, imidazolinones-, acetolactate synthase (ALS) inhibitors-, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) inhibitors-, protoporphyrinogen oxidase (PPO) inhibitors-, triazines-inhibitors, or bromoxynil-tolerant crops. Such herbicide tolerant crops may possesses multiple or stacked traits conferring tolerance to multiple herbicides or multiple modes-of-action. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 7-11, naznačen time što se nepoželjno raslinje kontrolira kod usjeva koji podnosi glifosat, glufosinat, dikambu, fenoksiauksine, piridiloksiauksine, ariloksifenoksipropionate, inhibitore acetil-CoA-karboksilaze (ACCaza), imidazolinone, inhibitore acetolaktat-sintaze (ALS), inhibitore 4- hidroksifenilpiruvat-dioksigenaze (HPPD), inhibitore protoporfirinogen-oksidaze (PPO), triazine, ili bromoksinil, gdje otporan usjev po mogućnosti ima višestruke ili kumulirane osobine koje omogućuju podnošenje višestrukih herbicida ili višestrukih načina djelovanja.
The composition of claim 19, wherein X is hydrobromic acid. 
Spoj prema zahtjevu 1, naznačen time što X je bromovodična kiselina.
A method for correcting or treating cognitive impairment in a subject suffering from Alzheimer's disease, the method comprising administering twice daily to said subject from 0.4 to 50 mg of acamprosate and from 6 to 15 mg of baclofen, or pharmaceutically acceptable salts thereof. 
Baklofen, ili njegova farmaceutski prihvatljiva sol, u kombinaciji s barem akamprozatom, ili njegovom farmaceutski prihvatljivom soli, za uporabu u poboljšanju kognitivnih simptoma u subjekta koji boluje od, ima predispoziciju ili se sumnja da boluje od Alzheimerove bolesti.
The pharmaceutical composition according to claim 3, wherein the pain is related to rheumatic disorders, arthritic disorders, painful joints, postoperative complaints, dental surgery, skin inflammation (dermatitis), skin lesions, skin cancer, mouth sores and/or athletic injuries. 
Farmaceutski pripravak prema zahtjevu 3, naznačen time da je bol povezana s reumatskim poremećajima, artritisnim poremećajima, bolnim zglobovima, postoperativnim pritužbama, stomatološkim zahvatima, upalom kože (dermatitis), kožnim lezijama, rakom kože, čirevima u ustima 1/ili atletskim ozljedama.
The compound of claim 1 selected from the group consisting of: 
Spoj iz patentnog zahtjeva 1, naznačen time, da je to spoj odabran iz sljedeće skupine: